Expect to report safety and early efficacy data from the Phase 1 dose-escalation study of ALX2004 in EGFR-expressing solid tumors and plan to host a KOL webinar to review the results in December 2026 Topline data from 120 patients in Phase 2 ASPEN-09-Breast clinical trial evaluating evorpacept in combination with trastuzumab and chemotherapy in HER2-positive metastatic breast cancer expected in 2H 2027 SOUTH SAN FRANCISCO, Calif., Nov. 16, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology," Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today reported financial results for the third quarter ended September 30, 2026, and provided a corporate update.
SOUTH SAN FRANCISCO, Calif., Nov. 10, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology"; Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced that ALX Oncology leadership will participate in fireside chats at three upcoming investor conferences.
U.S. markets were whipsawed by the midterm elections this week, as a decisive Democratic sweep of both chambers of Congress became another catalyst for the reassessment of the AI boom. Voters overwhelmingly rejected data-center development at the ballot box both locally and nationally, with 40 of 41 data-center measures producing outcomes favoring greater restrictions. Treasury yields and oil prices both fell sharply this week, as the prospect of a divided government bolstered expectations for greater fiscal discipline and a slower pace of deficit-financed spending.
Alexander's, Inc. (ALX) Q3 2026 Earnings Call Transcript
Vornado Realty Trust reported higher third-quarter comparable funds from operations and continued leasing momentum across its New York office portfolio, as management pointed to rising rents, tightening availability of high-quality space and substantial signed revenue yet to commence.
Alexander's (ALX) came out with quarterly funds from operations (FFO) of $7.07 per share, missing the Zacks Consensus Estimate of $8.2 per share. This compares to FFO of $2.91 per share a year ago.
PARAMUS, N.J., Nov. 02, 2026 (GLOBE NEWSWIRE) -- ALEXANDER'S, INC. (New York Stock Exchange: ALX) filed its Form 10-Q for the quarter ended September 30, 2026 today and reported:
Alexander's, Inc. (NYSE: ALX - Get Free Report)'s share price crossed above its 200-day moving average during trading on Friday. The stock has a 200-day moving average of $251.59 and traded as high as $254.50. Alexander's shares last traded at $252.02, with a volume of 80,050 shares changing hands. Wall Street Analyst Weigh In A number
PARAMUS, N.J., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Alexander's, Inc. (NYSE: ALX) today announced that its Board of Directors has declared a regular quarterly dividend of $4.50 per share payable on November 20, 2026 to stockholders of record on November 9, 2026.
PARAMUS, N.J., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Alexander's, Inc. (NYSE: ALX) today announced that it will file its quarterly report on Form 10-Q for the quarter ended September 30, 2026 with the U.S. Securities and Exchange Commission and issue its third quarter earnings release on Monday, November 2, 2026, before the New York Stock Exchange opens.